10-Q: Strata Skin Sciences Reports Third Quarter 2024 Results, Revenue Slightly Down Year-Over-Year

Strata Skin Sciences reports a slight decrease in revenue for the third quarter of 2024 compared to the same period last year, alongside a net loss, but shows improved gross profit margins.

Summary

• Strata Skin Sciences reported a net revenue of $8.8 million for the third quarter of 2024, a slight decrease from $8.9 million in the same quarter of 2023.
• The company's net loss for the quarter was $2.1 million, compared to a net loss of $1.1 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, the company's net revenue was $24 million, down from $24.7 million in the same period of 2023.
• The net loss for the first nine months of 2024 was $5.6 million, compared to a net loss of $7 million for the same period in 2023.
• The company's gross profit margin improved to 60.3% in the third quarter of 2024, up from 56% in the third quarter of 2023.
• The company had 873 XTRAC systems placed in dermatologists' offices in the U.S. as of September 30, 2024, a decrease from 923 at the end of 2023.
• The company sold 27 XTRAC systems domestically and internationally in the third quarter of 2024.
• The company sold 72 XTRAC systems domestically and internationally in the first nine months of 2024.
• The company recognized $864 of Employee Retention Credit as other income in the nine months ended September 30, 2024.
• The company's weighted average shares outstanding was 4,038,988 for the three months ended September 30, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed results with a slight decrease in revenue and an increase in net loss, but also shows improved gross profit margins. The company faces ongoing challenges with sales tax audits and supply chain issues, which contribute to a negative sentiment. The potential for further capital raising also adds to the uncertainty.

Positives

• Gross profit margin improved to 60.3% in the third quarter of 2024, up from 56% in the third quarter of 2023, driven by lower amortization costs and the sale of refurbished units.
• The company recognized $864 of Employee Retention Credit as other income in the nine months ended September 30, 2024.
• The company's weighted average shares outstanding was 4,038,988 for the three months ended September 30, 2024.

Negatives

• Third quarter revenue was $8.8 million, slightly down from $8.9 million in the same period last year.
• Net loss for the third quarter was $2.1 million, compared to a $1.1 million loss in the third quarter of 2023.
• The company placed 873 XTRAC systems in the U.S. as of September 30, 2024, down from 923 at the end of 2023.
• The company's net loss for the first nine months of 2024 was $5.6 million, compared to a net loss of $7 million for the same period in 2023.

Risks

• The company is subject to ongoing sales tax audits in New York and California, with potential liabilities of $5.2 million, including penalties and interest.
• The company's business is impacted by the COVID-19 pandemic, the Russia-Ukraine war, and the Middle East conflict, which have caused supply chain disruptions and volatility in financial markets.
• The company's supply of neon gas, essential for its lasers, is at risk due to the Russia-Ukraine war and increased demand from semiconductor manufacturers.
• The company's ability to access financing could be impacted by market conditions, including the negative impact of the COVID-19 pandemic, the Russia-Ukraine War, and the Middle East conflict on the financial markets, supply chain disruptions, customer behavior, and rising interest rates.

Future Outlook

The company believes that its cash and cash equivalents, combined with anticipated revenues and operating expense management, will be sufficient to satisfy its working capital needs for at least the next 12 months. However, market conditions could interfere with the company's ability to access financing on favorable terms.

Management Comments

• The company is focused on increasing its direct-to-patient advertising program for XTRAC in the United States.
• The company is monitoring the results of its advertising expenditures to effectively reach patients afflicted with psoriasis and vitiligo.
• The company believes that several factors have an impact on the prescribed use of XTRAC treatments for psoriasis and vitiligo patients, including a lack of awareness of the positive effects of XTRAC treatments among both sufferers and providers.

Industry Context

The company operates in the medical technology sector, specifically in dermatology, and competes with other companies offering treatments for psoriasis, vitiligo, and acne. The company's performance is affected by factors such as insurance coverage for its treatments, market acceptance of its products, and supply chain disruptions.

Comparison to Industry Standards

• Strata Skin Sciences' gross profit margin of 60.3% for the third quarter of 2024 is relatively strong compared to some medical device companies, but it is important to compare this to companies with similar business models, such as those focused on recurring revenue from placed devices.
• Companies like InMode and Cutera, which also operate in the aesthetic medical device space, have reported gross margins in the 60-70% range, but their product mix and business models differ from Strata's.
• The decrease in XTRAC system placements from 923 to 873 indicates a potential challenge in maintaining or growing the installed base, which is a key driver of recurring revenue. This should be compared to the placement rates of competitors' devices.
• The company's net loss of $2.1 million for the quarter is not unusual for a growth-stage medical device company, but it is important to monitor the trend and compare it to peers with similar revenue levels and growth trajectories.
• The company's reliance on a single major customer for a significant portion of its revenue (13.2% for the nine months ended September 30, 2024) is a risk factor that should be compared to the customer concentration of other companies in the industry.

Legal Proceedings

• The company is subject to ongoing sales tax audits in New York and California, with potential liabilities of $5.2 million, including penalties and interest.
• The company received an adverse decision from the New York State Appellate Division regarding sales tax on XTRAC treatment codes, and the New York State Court of Appeals denied the company's motion to appeal the Appellate Division ruling.
• The company is in the administrative process of appeal with respect to the remaining $1.3 million of assessments in the State of New York.
• The company is in the administrative process of appeal with respect to assessments of $2.1 million in the State of California.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and the potential for further capital raising.
• Employees may be affected by the company's cost-cutting measures and the reduction in the size of the sales force.
• Customers may be impacted by the company's supply chain disruptions and the availability of its products.
• Creditors may be concerned about the company's financial performance and its ability to repay its debt.

Next Steps

• The company plans to increase its direct-to-patient advertising program for XTRAC in the United States.
• The company will continue to monitor the results of its advertising expenditures.
• The company will continue to manage its operating expenses and monitor its cash flow.

Key Dates

Keywords

XTRAC, dermatology, laser, psoriasis, vitiligo, TheraClear, revenue, net loss, gross profit, medical technology, skin conditions